Track market-moving stories before they get noisy

3 Energy Stocks to Watch Now as LNG Demand SurgesEQT Corp. announced an agreement to acquire Range Resources NYSE: RRC in an all-stock transaction that the companies said would create a larger, vertically integrated Appalachian natural gas platform focused on serving anticipated growth in domestic power generation, pipeline takeaway and international markets.

Under the agreement, Range shareholders would receive 0.987 shares of EQT common stock for each Range share they own. EQT shareholders are expected to own about 73% of the combined company at closing, with Range shareholders owning the remaining 27%. EQT Chief Financial Officer Jeremy Knop said the transaction implies a pro forma enterprise value of more than $50 billion.

Get Range Resources alerts:

These energy stocks are most-upgraded amid falling oil pricesEQT President and CEO Toby Rice said the combination would unite adjacent resource positions in southwest and northeast Pennsylvania, providing more flexibility in development sequencing, infrastructure use and volume flows. He said EQT sees more than 30 years of inventory across the combined company and projects a pro forma unlevered free-cash-flow breakeven below $2 per MMBtu.

Demand growth drives timing
Rice said the emerging demand outlook in Appalachia was a key catalyst for pursuing the deal. EQT cited prospective natural gas demand tied to new power-generation facilities, pipeline infrastructure and industrial development, particularly around the Clarington, Ohio, delivery point and along the Ohio River.

10 Best Natural Gas Stocks to Buy NowDuring the question-and-answer session, Knop said EQT had increased its estimate for potential Appalachian natural gas demand to 25 Bcf per day from a previously discussed level near 20 Bcf per day. He said the company continues to see momentum in discussions with parties across the value chain.

Rice said EQT’s existing productive capacity could exceed 12 Bcf per day, while Range has stated it could potentially produce 5 Bcf per day and sustain that level for 15 years. Together, he said, the companies could have productive capacity of about 17 Bcf per day.

However, Rice said future production growth would remain tied to confirmed customer demand rather than being pursued as a standalone target. EQT expects mid-single-digit growth to be achievable, but management said it intends to continue emphasizing “sustainable growth” supported by contracted demand.

Synergies and commercial opportunities
EQT identified $325 million in annual base synergies, primarily from corporate, organizational and operating efficiencies. Knop said the bulk of those savings are expected to be reflected in operating expenses rather than reduced capital expenditures.

The company also cited more than $300 million in potential additional annual long-term synergy upside from midstream system optimization, gas, LNG and LPG marketing, premium supply agreements and the accelerated development of inventory into demand growth. Management noted that these opportunities may take longer to translate into cash flow than conventional cost synergies because some depend on the construction of new infrastructure and customer facilities.

Rice said EQT would assess opportunities to add compression and optimize gathering systems across the Range asset base, characterizing compression investments as potentially high-return and fast-payback projects. He said the companies do not expect significant changes to Range’s development schedule during the first 12 months after closing.

Management also highlighted commercial opportunities from combining EQT’s marketing platform with Range’s production and liquids exposure. Knop said EQT generated approximately $200 million of incremental free cash flow from its commodities organization in the prior year and expects broader scale to support additional optimization.

EQT currently has nearly 1 Bcf per day of international market exposure through LNG contracts. Rice said maintaining roughly 15% of production exposure to international markets could provide capacity for approximately 2 million tons per annum of additional LNG associated with Range volumes, depending on the attractiveness of future opportunities.

Balance sheet and shareholder returns
Knop said the all-equity structure would strengthen EQT’s balance sheet and support its objective of achieving BBB or equivalent credit ratings from all agencies by early 2027. EQT set a pro forma maximum debt target of 1x net debt to adjusted EBITDA at a $2.75 per MMBtu NYMEX natural gas price.

At that gas-price assumption, EQT projects nearly $14 billion in cumulative pro forma free cash flow over five years. Under a $5 per MMBtu scenario, it projected cumulative five-year free cash flow of more than $38 billion.

Rice said EQT’s capital-allocation framework would remain largely unchanged, including disciplined investment, modest dividend growth, cash accumulation and opportunistic share repurchases. He said the transaction’s deleveraging effect, expected free-cash-flow-per-share accretion and projected synergies could provide more flexibility for buybacks.

Range President and CEO Dennis Degner said Range’s board concluded that combining with EQT offered the best opportunity to accelerate shareholder value through greater scale, infrastructure access and market reach. He said Range remains on track to execute the final year of its multiyear growth plan in 2027.

About Range Resources (NYSE:RRC)Range Resources Corporation is an independent natural gas, natural gas liquids and oil exploration and production company. Its operations are concentrated in the Appalachian Basin, particularly the Marcellus Shale in southwestern Pennsylvania, where the company develops unconventional wells and produces natural gas, condensate and natural gas liquids.

The company's activities include leasing and developing mineral properties, drilling and completing horizontal wells, and producing and marketing hydrocarbons.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Range Resources Right Now?Before you consider Range Resources, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Range Resources wasn't on the list.

While Range Resources currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Fee Only Financial Planning L.C. acquired a new position in C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW – Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 7,666 shares of the transportation company’s stock, valued at approximately $1,134,000. C.H. Robinson Worldwide comprises about 0.6% of Fee Only Financial Planning L.C.’s holdings, making the stock its 17th largest holding.

Other institutional investors and hedge funds have also recently modified their holdings of the company. WCM Investment Management LLC acquired a new stake in C.H. Robinson Worldwide in the first quarter valued at approximately $579,922,000. Dimensional Fund Advisors LP grew its holdings in C.H. Robinson Worldwide by 2.4% in the first quarter. Dimensional Fund Advisors LP now owns 1,094,992 shares of the transportation company’s stock worth $181,810,000 after purchasing an additional 25,674 shares during the last quarter. Bank of America Corp DE increased its position in shares of C.H. Robinson Worldwide by 13.7% during the first quarter. Bank of America Corp DE now owns 1,055,602 shares of the transportation company’s stock worth $175,304,000 after purchasing an additional 127,103 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of C.H. Robinson Worldwide during the second quarter worth $172,626,000. Finally, Hamlin Capital Management LLC purchased a new stake in shares of C.H. Robinson Worldwide during the 3rd quarter valued at $123,176,000. Hedge funds and other institutional investors own 93.15% of the company’s stock.

C.H. Robinson Worldwide Stock Performance
Shares of C.H. Robinson Worldwide stock opened at $141.17 on Monday. The company has a current ratio of 1.58, a quick ratio of 1.58 and a debt-to-equity ratio of 1.04. C.H. Robinson Worldwide, Inc. has a 12-month low of $125.41 and a 12-month high of $210.33. The firm has a market capitalization of $16.50 billion, a price-to-earnings ratio of 26.94, a PEG ratio of 1.17 and a beta of 0.94. The firm’s 50 day simple moving average is $146.52 and its two-hundred day simple moving average is $166.94.

C.H. Robinson Worldwide (NASDAQ:CHRW – Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The transportation company reported $1.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.53 by $0.08. C.H. Robinson Worldwide had a net margin of 3.73% and a return on equity of 38.36%. The business had revenue of $4.93 billion during the quarter, compared to analysts’ expectations of $4.35 billion. During the same quarter last year, the company posted $1.29 earnings per share. The business’s quarterly revenue was up 19.3% on a year-over-year basis. Analysts predict that C.H. Robinson Worldwide, Inc. will post 6.26 EPS for the current year.
C.H. Robinson Worldwide Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Friday, October 2nd. Investors of record on Friday, September 4th were given a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 1.8%. The ex-dividend date of this dividend was Friday, September 4th. C.H. Robinson Worldwide’s dividend payout ratio is presently 48.09%.

Analyst Upgrades and Downgrades
CHRW has been the subject of a number of recent analyst reports. Sanford C. Bernstein reissued a “market perform” rating on shares of C.H. Robinson Worldwide in a research report on Tuesday, October 6th. Weiss Ratings downgraded C.H. Robinson Worldwide from a “hold (c+)” rating to a “hold (c)” rating in a research note on Tuesday, September 1st. Jefferies Financial Group reaffirmed a “buy” rating and set a $220.00 target price on shares of C.H. Robinson Worldwide in a research report on Tuesday, October 6th. Janney Montgomery Scott set a $155.00 price target on C.H. Robinson Worldwide in a research note on Tuesday, July 28th. Finally, Freedom Capital upgraded C.H. Robinson Worldwide from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $190.00.

Get Our Latest Stock Analysis on C.H. Robinson Worldwide

(Free Report)

C.H. Robinson Worldwide, Inc is a global third-party logistics provider that connects shippers with transportation carriers and other supply-chain resources. The company arranges the movement of freight by truckload, less-than-truckload, intermodal, ocean and air transportation, serving businesses across a range of industries.

Its services include freight brokerage, transportation management, logistics consulting, customs and trade support, shipment tracking, and technology-enabled supply-chain solutions.

Further Reading

Five stocks we like better than C.H. Robinson Worldwide
Newmont’s Record Quarter Shows Why Gold’s Floor Is the Real Story
Albemarle Upgrade: Can Energy Storage Recharge Lithium’s Leader?
Consumer Staples Are Up 12% This Year—These 3 Beverage Stocks Are Leading the Way
Can Planet Fitness Get Its Growth Back in Shape?

Want to see what other hedge funds are holding CHRW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW – Free Report).

Receive News & Ratings for C.H. Robinson Worldwide Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.H. Robinson Worldwide and related companies with MarketBeat.com's FREE daily email newsletter.

Have you evaluated the performance of Equifax's (EFX - Free Report) international operations for the quarter ending September 2026? Given the extensive global presence of this credit reporting company, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth.

The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has become essential for investors to comprehend how much a company relies on these foreign markets, as this understanding reveals the firm's potential for consistent earnings, its capacity to harness different economic cycles, and its overall growth prospects.

Being present in foreign markets serves as protection against local economic declines and helps benefit from more rapidly expanding economies. Yet, such expansion also introduces challenges related to currency fluctuations, geopolitical uncertainties and varied market behaviors.

Upon examining EFX's recent quarterly performance, we noticed several interesting patterns in the revenue generated from its international segments, which are commonly analyzed and observed by Wall Street experts.

For the quarter, the company's total revenue amounted to $1.69 billion, experiencing an increase of 9.6% year over year. Next, we'll explore the breakdown of EFX's international revenue to understand the importance of its overseas business operations.

Trends in EFX's Revenue from International MarketsDuring the quarter, Canada contributed $72.2 million in revenue, making up 4.3% of the total revenue. When compared to the consensus estimate of $72.8 million, this meant a surprise of -0.83%. Looking back, Canada contributed $73.3 million, or 4.3%, in the previous quarter, and $70.8 million, or 4.6%, in the same quarter of the previous year.

Of the total revenue, $105.5 million came from Europe during the last fiscal quarter, accounting for 6.2%. This represented a surprise of -0.46% as analysts had expected the region to contribute $105.99 million to the total revenue. In comparison, the region contributed $101.1 million, or 6%, and $102.3 million, or 6.6%, to total revenue in the previous and year-ago quarters, respectively.

Asia Pacific generated $107.7 million in revenues for the company in the last quarter, constituting 6.4% of the total. This represented a surprise of +8.25% compared to the $99.49 million projected by Wall Street analysts. Comparatively, in the previous quarter, Asia Pacific accounted for $99.7 million (5.9%), and in the year-ago quarter, it contributed $90.1 million (5.8%) to the total revenue.

Latin America accounted for 6.7% of the company's total revenue during the quarter, translating to $114.1 million. Revenues from this region represented a surprise of +4.15%, with Wall Street analysts collectively expecting $109.56 million. When compared to the preceding quarter and the same quarter in the previous year, Latin America contributed $109 million (6.4%) and $102.1 million (6.6%) to the total revenue, respectively.

Prospective Revenues in International MarketsIt is projected by analysts on Wall Street that Equifax will post revenues of $1.62 billion for the ongoing fiscal quarter, an increase of 4.5% from the year-ago quarter. The expected contributions from Canada, Europe, Asia Pacific and Latin America to this revenue are 4.4%, 6.8%, 6%, and 7.1%, translating into $70.79 million, $110.08 million, $96.48 million, and $114.27 million, respectively.

Analysts expect the company to report a total annual revenue of $6.68 billion for the full year, marking an increase of 10% compared to last year. The expected revenue contributions from Canada, Europe, Asia Pacific and Latin America are projected to be 4.3% ($287.7 million), 6.2% ($412.02 million)5.9% ($392.36 million) and 6.6% ($439.08 million) of the total revenue, in that order.

Wrapping UpEquifax's leaning on foreign markets for its revenue stream presents a mix of chances and challenges. Therefore, a vigilant watch on its international revenue movements can greatly aid in projecting the company's future direction.

In a world where international interdependencies and geopolitical conflicts are ever-increasing, Wall Street analysts closely monitor these trends for companies having international presence to adjust their earnings forecasts. Of course, there are several other factors, including a company's standing within its home borders, that influence analysts' earnings forecasts.

At Zacks, we place significant importance on a company's evolving earnings outlook. This is based on empirical evidence demonstrating its strong influence on a stock's short-term price movements. Invariably, there exists a positive relationship -- an upward revision in earnings estimates is typically mirrored by a rise in the stock price.

The Zacks Rank, our proprietary stock rating mechanism, demonstrates a notable performance history confirmed through external audits. It effectively utilizes the power of earnings estimate revisions to act as a predictor of a stock's price performance in the near term.

Equifax currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Equifax's Recent Stock Market PerformanceOver the past month, the stock has gained 23.1% versus the Zacks S&P 500 composite's 1.2% decrease. The Zacks Business Services sector, of which Equifax is a part, has risen 3.5% over the same period. The company's shares have increased 5.6% over the past three months compared to the S&P 500's 2.5% increase. Over the same period, the sector has risen 1.7%

Lead Plaintiff Deadline: December 21, 2026. Investors who sold shares of Skechers Class A common stock from April 24, 2025 through September 12, 2025, including those who sold shares in the Take-Private acquisition (the “Take-Private Acquisition”) of Skechers by 3G Capital Partners L.P. and its affiliates on September 12, 2025. may be eligible to recover losses.

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Attorney Advertising -- This lawsuit has been filed against Skechers U.S.A., Inc. (“Skechers” or the “Company”) and certain of its officers and directors (collectively, the “Skechers Defendants”), as well as 3G Capital Partners L.P., Greenhill & Co., LLC and related defendants (collectively, “Defendants”), as well as 3G Capital Partners L.P., Greenhill & Co., LLC and related defendants (collectively, “Defendants”)on behalf of a class (the “Class”) consisting of all persons or entities that sold shares of Skechers Class A common stock from April 24, 2025 through September 12, 2025, including those who sold shares in the Take-Private acquisition (the “Take-Private Acquisition”) of Skechers by 3G Capital Partners L.P. and its affiliates on September 12, 2025. Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/cases/skechers-usa-inc-skx-class-action-lawsuit.

Skechers Case Details

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and omitted material facts concerning Skechers’ Take-Private Acquisition in the April 24, 2025 Information Statement and related public reports. Specifically, the Complaint alleges that the Skechers Defendants:

 (1) falsely represented that the acquisition and the $63 per share consideration were fair; (2)made misleading statements about the mixed merger consideration and the impact of U.S. and China tariffs on the Company; and (3) misled investors about strategic alternatives and efforts to explore those alternatives. The Complaint further alleges that certain Defendants, including 3G Capital and Greenhill, engaged in a scheme to deceive Skechers shareholders.

What's Next for Skechers Investors?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/cases/skechers-usa-inc-skx-class-action-lawsuit or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Skechers you have until December 21, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

No Cost to Skechers Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Skechers Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]

Attorney advertising.
Prior results do not guarantee similar outcomes.

On its third-quarter 2026 earnings call, held on Oct. 23, 2026, Glacier Bancorp (GBCI +1.12%) reported record quarterly net income of $105 million. Higher yields on new loans and expanding profit margins are compounding earnings power across its regional footprint.

Three things management said stand out.

1. Asset Repricing Drives Net Interest Margin ExpansionNet interest margin, which measures profitability on lending, surpassed 4% as maturing loans and securities rolled into higher market yields. About $3.5 billion in loans will reprice higher over the coming year to sustain this momentum.

Loan repricing, approximately $3.5 billion of loans currently in portfolio will reprice up 125 to 150 basis points in the next 12 months.
-- Byron Pollan, Deputy CFO and Treasurer2. Noninterest-Bearing Deposits Lower Overall Funding CostsNoninterest-bearing deposits, which are checking accounts that pay zero interest, grew at a 15% annualized rate. This core deposit growth allowed the bank to fund loan expansion while trimming overall deposit costs.

And the real highlight this quarter was our growth in our noninterest-bearing balances. That was fantastic.
-- Byron Pollan, Deputy CFO and Treasurer3. Accumulating Capital Opens Opportunities for BuybacksAccelerating net income is building capital reserves beyond immediate operating needs. Management is evaluating share repurchases and special dividends, which return cash to shareholders, to optimize its balance sheet.

So all -- we are really now going to take a look at all options, including special dividends and share buybacks because of the amount of capital we see accumulating, and we really just want to make sure we have all levers available to us.
-- Randall Chesler, President and CEOLooking AheadNet interest income is building momentum as fixed-rate assets reprice higher, and management isn't hiding its satisfaction about it. Strong core deposit growth and expanding margins give the bank structural funding advantages across its Western markets. Leadership is watching deposit costs and asset yields closely.

So we do have some meaningful momentum on the asset repricing, and that's going to carry us through with increasing margins through '27.
-- Byron Pollan, Deputy CFO and TreasurerDisciplined underwriting and community relationships position the bank for sustained earnings power. Expanding capital reserves will support future growth and shareholder returns.

We are very encouraged by our results for the third quarter and through the first 9 months of the year.
-- Randall Chesler, President and CEOThe Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The Industrial Products group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Albany International (AIN - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.

Albany International is a member of the Industrial Products sector. This group includes 188 individual stocks and currently holds a Zacks Sector Rank of #10. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Albany International is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for AIN's full-year earnings has moved 20.4% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.

Based on the most recent data, AIN has returned 23.5% so far this year. At the same time, Industrial Products stocks have gained an average of 9%. As we can see, Albany International is performing better than its sector in the calendar year.

Another Industrial Products stock, which has outperformed the sector so far this year, is Emerson Electric (EMR - Free Report) . The stock has returned 21.8% year-to-date.

For Emerson Electric, the consensus EPS estimate for the current year has increased 1.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).

To break things down more, Albany International belongs to the Textile - Products industry, a group that includes 2 individual companies and currently sits at #30 in the Zacks Industry Rank. On average, stocks in this group have gained 26.5% this year, meaning that AIN is slightly underperforming its industry in terms of year-to-date returns.

On the other hand, Emerson Electric belongs to the Manufacturing - Electronics industry. This 14-stock industry is currently ranked #88. The industry has moved +16.2% year to date.

Investors with an interest in Industrial Products stocks should continue to track Albany International and Emerson Electric. These stocks will be looking to continue their solid performance.

Allison Transmission (ALSN - Free Report) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on November 2. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis automatic transmission maker is expected to post quarterly earnings of $2.47 per share in its upcoming report, which represents a year-over-year change of +51.5%.

Revenues are expected to be $1.47 billion, up 111.8% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.63% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Allison Transmission?For Allison Transmission, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -2.83%.

On the other hand, the stock currently carries a Zacks Rank of #4.

So, this combination makes it difficult to conclusively predict that Allison Transmission will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Allison Transmission would post earnings of $2.6 per share when it actually produced earnings of $2.73, delivering a surprise of +5.00%.

Over the last four quarters, the company has beaten consensus EPS estimates three times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Allison Transmission doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Expected Results of an Industry PlayerBorgWarner (BWA - Free Report) , another stock in the Zacks Automotive - Original Equipment industry, is expected to report earnings per share of $1.24 for the quarter ended September 2026. This estimate points to no change from the year-ago quarter. Revenues for the quarter are expected to be $3.51 billion, down 2.3% from the year-ago quarter.

The consensus EPS estimate for BorgWarner has been revised 1.1% lower over the last 30 days to the current level. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -1.45%.

When combined with a Zacks Rank of #3 (Hold), this Earnings ESP makes it difficult to conclusively predict that BorgWarner will beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Organon (OGN - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Shares of this pharmaceutical company have returned +0.2% over the past month versus the Zacks S&P 500 composite's -1.2% change. The Zacks Medical Services industry, to which Organon belongs, has gained 5.4% over this period. Now the key question is: Where could the stock be headed in the near term?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current quarter, Organon is expected to post earnings of $0.91 per share, indicating a change of -9.9% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.

For the current fiscal year, the consensus earnings estimate of $3.37 points to a change of -7.9% from the prior year. Over the last 30 days, this estimate has remained unchanged.

For the next fiscal year, the consensus earnings estimate of $3.61 indicates a change of +7% from what Organon is expected to report a year ago. Over the past month, the estimate has remained unchanged.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Organon is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

In the case of Organon, the consensus sales estimate of $1.57 billion for the current quarter points to a year-over-year change of -2.2%. The $6.08 billion and $6.09 billion estimates for the current and next fiscal years indicate changes of -2.1% and +0.1%, respectively.

Last Reported Results and Surprise HistoryOrganon reported revenues of $1.56 billion in the last reported quarter, representing a year-over-year change of -2.3%. EPS of $0.85 for the same period compares with $1 a year ago.

Compared to the Zacks Consensus Estimate of $1.54 billion, the reported revenues represent a surprise of +1.09%. The EPS surprise was -2.3%.

Over the last four quarters, the company surpassed EPS estimates just once. The company topped consensus revenue estimates two times over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Organon is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Organon. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

The market expects Vitesse Energy (VTS - Free Report) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on November 2. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis energy company is expected to post quarterly earnings of $0.01 per share in its upcoming report, which represents a year-over-year change of +133.3%.

Revenues are expected to be $85.1 million, up 26.2% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 50% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Vitesse?For Vitesse, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. This has resulted in an Earnings ESP of 0%.

On the other hand, the stock currently carries a Zacks Rank of #2.

So, this combination makes it difficult to conclusively predict that Vitesse will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Vitesse would post earnings of $0.06 per share when it actually produced earnings of $0.05, delivering a surprise of -16.67%.

The company has not been able to beat consensus EPS estimates in any of the last four quarters.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Vitesse doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

An Industry Player's Expected ResultsAnother stock from the Zacks Oil and Gas - Exploration and Production - United States industry, Vitesse Energy (VTS - Free Report) , is soon expected to post earnings of $0.01 per share for the quarter ended September 2026. This estimate indicates a year-over-year change of +133.3%. Revenues for the quarter are expected to be $85.1 million, up 26.2% from the year-ago quarter.

Over the last 30 days, the consensus EPS estimate for Vitesse has been revised 50% up to the current level. Nevertheless, the company now has an Earnings ESP of 0.00%, reflecting an equal Most Accurate Estimate.

When combined with a Zacks Rank of #2 (Buy), this Earnings ESP makes it difficult to conclusively predict that Vitesse will beat the consensus EPS estimate. The company could not beat consensus EPS estimates in any of the last four quarters.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

#1 (Strong Buy) stocks have produced an unmatched +23.82% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Knight-Swift Transportation Holdings (KNX - Free Report) Knight-Swift Transportation Holdings Inc. is one of North America's largest and most diversified freight transportation companies, providing multiple full truckload, LTL, intermodal and other complementary services. Knight-Swift utilizes a nationwide network of business units and terminals across the United States and Mexico to serve customers throughout North America. Apart from operating one of the country's largest truckload fleets, Knight-Swift also contracts with third-party carriers to provide a broad range of transportation services to customers while providing quality driving jobs for driving associates and successful business opportunities for independent contractors. The company is based in Phoenix, AZ.

KNX is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

Additionally, the company could be a top pick for growth investors. KNX has a Growth Style Score of A, forecasting year-over-year earnings growth of 85.7% for the current fiscal year.

For fiscal 2026, five analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.06 to $2.34 per share. KNX boasts an average earnings surprise of +6.3%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, KNX should be on investors' short list.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about SharkNinja, Inc. (SN - Free Report) .

SharkNinja, Inc. currently has an average brokerage recommendation (ABR) of 1.17, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 12 brokerage firms. An ABR of 1.17 approximates between Strong Buy and Buy.

Of the 12 recommendations that derive the current ABR, 11 are Strong Buy, representing 91.7% of all recommendations.

Brokerage Recommendation Trends for SN

Check price target & stock forecast for SharkNinja, Inc. here>>>

While the ABR calls for buying SharkNinja, Inc., it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.

Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.

This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.

With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.

ABR Should Not Be Confused With Zacks RankAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.

Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.

On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.

There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.

Should You Invest in SN?Looking at the earnings estimate revisions for SharkNinja, Inc., the Zacks Consensus Estimate for the current year has increased 0.1% over the past month to $6.55.

Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for SharkNinja, Inc. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Therefore, the Buy-equivalent ABR for SharkNinja, Inc may serve as a useful guide for investors.

The market expects PSEG (PEG - Free Report) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

The earnings report, which is expected to be released on November 2, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis parent company of PSEG Power and Public Service Electric & Gas Co. is expected to post quarterly earnings of $1.22 per share in its upcoming report, which represents a year-over-year change of +8%.

Revenues are expected to be $3.29 billion, up 2% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 6.47% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for PSEG?For PSEG, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. This has resulted in an Earnings ESP of 0%.

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination makes it difficult to conclusively predict that PSEG will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that PSEG would post earnings of $0.8 per share when it actually produced earnings of $0.86, delivering a surprise of +7.50%.

Over the last four quarters, the company has beaten consensus EPS estimates four times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

PSEG doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Expected Results of an Industry PlayerAmong the stocks in the Zacks Utility - Electric Power industry, Edison International (EIX - Free Report) , is soon expected to post earnings of $1.79 per share for the quarter ended September 2026. This estimate indicates a year-over-year change of -23.5%. This quarter's revenue is expected to be $5.53 billion, down 3.8% from the year-ago quarter.

Over the last 30 days, the consensus EPS estimate for Edison International has been revised 11.4% down to the current level. Nevertheless, the company now has an Earnings ESP of +1.12%, reflecting a higher Most Accurate Estimate.

This Earnings ESP, combined with its Zacks Rank #3 (Hold), suggests that Edison International will most likely beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced findings from a new clinical outcomes study showing significant improvements in menopause symptoms among members receiving care through its Menopause and Midlife program. The research found that more than 70% of members in the study experienced improvement in their menopause symptoms, with the greatest gains observed among those who received both personalized coaching and care from menopause-trained providers.

The findings, detailed in Progyny's new white paper, Beyond the Hype: Evidence for a Connected Model of Menopause Care, come during Menopause Awareness Month and as demand for menopause support continues to grow, yet access to evidence-based care remains limited, inconsistent, and difficult to navigate. In an expanding marketplace of menopause solutions offering widely varying levels of clinical support, the research underscores the importance of a connected care model that integrates education, personalized guidance, and specialized clinical care to help women navigate this critical life stage.

“Menopause has historically been underdiscussed and undertreated. Growing awareness is an important step forward, but awareness alone isn’t enough,” said Dr. Janet Choi, Chief Medical Officer, Progyny. “Women need reliable education and access to knowledgeable providers who offer evidence-based care tailored to their individual symptoms, health needs and goals. With so many products and treatments promoted today, employers also need confidence that the benefits they invest in connect employees to care grounded in clinical best practices, tailored to improve their health and well-being.”

Key findings from the study include:

More than 70% of members in the study experienced symptom improvement: 70.8% of members reported an overall improvement in menopause symptoms, with an average 7.1-point improvement on the Menopause Rating Scale (MRS), a validated assessment of 11 common symptoms scored in severity on a scale from 0 to 44.Coaching plus menopause-trained provider care was associated with the greatest improvements: Members who received both experienced an average 7.6-point improvement in MRS scores, compared with 3.3 points among those who received coaching alone.Significant improvements were observed across all 11 measured symptoms: Members experienced reductions in hot flashes (52%), vaginal dryness (50%), cardiac symptoms (48%), and depressive mood (45%), among other symptoms.Sleep disturbance fell 42%, addressing a symptom linked to cardiometabolic risk.Women with severe symptoms also experienced meaningful relief: 40.4% of members who initially reported severe symptoms moved into a lower symptom severity category.
Addressing a growing gap in menopause care

Despite increasing attention to menopause in the workplace, many women continue to face challenges finding qualified providers and navigating treatment options. As recently as 2023, fewer than one-third of OB-GYN residency programs included menopause management training, contributing to gaps in specialized care.

These challenges have a direct impact on employee well-being and performance. Research published in Mayo Clinic Proceedings estimated that menopause-related symptoms contribute to $1.8 billion in annual lost productivity in the United States due to missed workdays alone.

Progyny's findings highlight the potential value of a more comprehensive approach to menopause support. Its Menopause and Midlife program combines evidence-based education, one-on-one coaching from clinically trained Progyny Care Advocates, and access to a curated network of menopause-trained providers. The model is designed to help members understand their symptoms, navigate treatment options, and access appropriate clinical care based on individual needs.

“A few months ago...the only thing I knew about menopause was that hot flashes were involved. While I was having hot flashes, the brain fog and joint pain were more debilitating. I felt like a shell of a human when I first contacted Progyny. [My Progyny Care Advocate] was very supportive, kind, understanding, and patient. She oriented me on my benefit and connected me with [a menopause provider]. I have a new lease on life. I feel so fortunate,” said one Progyny member.

The full white paper, Beyond the Hype: Evidence for a Connected Model of Menopause Care, is available here.

About Progyny

Progyny is a global leader in women’s health and family building solutions, trusted by leading employers, health plans, and benefit purchasers worldwide. Through its comprehensive and personalized approach, Progyny supports members across fertility and family building, pregnancy and postpartum, menopause and midlife, and parent and child well-being journeys. Progyny combines differentiated clinical care, integrated pharmacy support through Progyny Rx®, and personalized guidance from Progyny Care Advocates® to deliver improved member experiences and better health outcomes. For more information, visit www.progyny.com.

About the study

The analysis was a retrospective longitudinal review of members enrolled in Progyny's Menopause and Midlife program during 2025–2026. The clinical outcomes sample included 179 members who completed an initial Menopause Rating Scale assessment during their first coaching call and a follow-up assessment an average of 109 days later. Findings reflect observed associations within the study population and do not establish causation.

For Further Information, Please Contact:

Media:
Alexis Ford
[email protected]

Investors:
James Hart
[email protected]

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

It also includes access to the Zacks Style Scores.

What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.82% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Ollie's Bargain Outlet (OLLI - Free Report) Headquartered in Harrisburg, PA, Ollie’s Bargain Outlet Holdings, Inc. is a value retailer of brand-name merchandise at drastically reduced prices. The company principally buys and sells overproduced, overstocked and closeout merchandise from manufacturers, wholesalers and other retailers, supplementing its name-brand closeout offerings with directly sourced private-label products in select key merchandise categories.

OLLI is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

Momentum investors should take note of this Consumer Staples stock. OLLI has a Momentum Style Score of B, and shares are up 4.1% over the past four weeks.

Six analysts revised their earnings estimate higher in the last 60 days for fiscal 2027, while the Zacks Consensus Estimate has increased $0.18 to $4.61 per share. OLLI also boasts an average earnings surprise of +8.9%.

With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, OLLI should be on investors' short list.

New York, New York--(Newsfile Corp. - October 26, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS) on behalf of investors that purchased or otherwise acquired Doximity common stock between August 8, 2024 and May 13, 2026 (the "Class Period").

CLICK HERE TO JOIN THE CASE

If you are an investor in Doximity and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.

DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than November 16, 2026 for an opportunity to be lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

The complaint alleges that throughout the Class Period, Doximity claimed that the Company's Newsfeed was its "biggest revenue driver." The truth – that Doximity overstated the impact that its Newsfeed would have on its revenue growth, and that the Company was losing market share to its competitors with more favorable pricing and engagement models – was allegedly revealed through a series of disclosures ending on May 13, 2026 when Doximity announced that it missed its already-reduced revenue guidance for the fiscal year ending March 31, 2026. Following this news, the price of Doximity stock declined by $5.38 per share, or 23%, on May 14, 2026.

CLICK HERE TO LEARN MORE

WHY CONTACT KAPLAN FOX?

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.

Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.

For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.

If you have any questions about this Notice, your rights, or your interests, please contact:

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

https://www.kaplanfox.com/case/doximity-nyse-docs-class-action-lawsuit-learn-more-now/

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320913

Source: Kaplan Fox & Kilsheimer LLP

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Brand's most ambitious holiday campaign yet puts consumers first by helping them discover meaningful gifts and create moments of wonder Brand's most ambitious holiday campaign yet puts consumers first by helping them discover meaningful gifts and create moments of wonder

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in AST SpaceMobile, Inc. (NASDAQ: ASTS) that a class action has been filed on behalf of shareholders who purchased securities between March 4, 2025 and July 15, 2026. Find out if you might qualify for recovery. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

The steepest single-session per-share loss of the Class Period came on February 12, 2026, when ASTS fell $14.70, or 15.17%, to close at $82.22 after the pricing of a second $1.0 billion convertible note offering. The lead plaintiff deadline is November 13, 2026.

What the Company Disclosed

SEC filings stated in the 2024 annual report that cash on hand and access to the 2024 ATM Equity Program "will be sufficient to meet our current working capital needs, planned operating expenses and capital expenditures for a period of the next 12 months." Quarterly reports covering the first three quarters of 2025 repeated substantially the same liquidity representation. Each report carried Sarbanes-Oxley certifications signed by senior management.

Disclosure Gaps Alleged

The complaint challenges whether that standardized language conveyed what was allegedly already developing inside the business:

Liquidity representations allegedly did not signal that capital requirements would produce $3.0 billion in convertible senior notes across October 2025, February 2026, and July 2026.The July 15, 2026 offering announcement stated the Company "currently does not have any understandings or agreements with respect to any such strategic transactions" while proceeds were earmarked for partnerships and acquisitions.Disclosure language indicated a durable competitive lead in satellite direct-to-cellular service without addressing the $19 billion EchoStar S-Band spectrum sale to SpaceX, according to the lawsuit.Filings allegedly omitted evidence of slow user adoption in the U.S. and Japan, a point later cited in a January 6, 2026 analyst downgrade.Initial conversion prices of approximately $116.30 (February 2026) and $79.57 (July 2026) reflected dilution the complaint contends investors were not prepared for. Why Generic Warnings May Not Protect

Risk factors written in conditional terms describe what could happen. The action contends that certain conditions described as possibilities were, in fact, already materializing during the Class Period, and that repeating the same twelve-month sufficiency language each quarter did not correct the picture investors were given.

"Generic risk factor language cannot substitute for disclosing specific, known problems that are already affecting a company's operations. Here, the complaint alleges that routine liquidity assurances were repeated quarter after quarter while capital requirements were building toward $3.0 billion in convertible notes issued over roughly nine months." -- Joseph E. Levi, Esq.

Submit your information now or call (212) 363-7500.

Levi & Korsinsky, LLP is a nationally recognized shareholder rights firm. Over the past 20 years, the firm has secured hundreds of millions of dollars for aggrieved shareholders. Ranked in ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the ASTS Lawsuit

Q: When did AST SpaceMobile allegedly mislead investors? A: The Class Period runs from March 4, 2025 to July 15, 2026. The complaint alleges that corrective disclosures revealed information that caused a significant stock decline.

Q: What court was the ASTS class action filed in? A: The case was filed in the United States District Court for the Western District of Texas, Midland/Odessa Division, governed by the Private Securities Litigation Reform Act of 1995.

Q: Who are the defendants named in the ASTS lawsuit? A: The complaint names AST SpaceMobile, Inc. and individual defendants including senior executives who signed SEC filings, made public statements, or certified financial disclosures under Sarbanes-Oxley.

Q: What documents do I need to submit my information? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What happens after I contact Levi & Korsinsky? A: An attorney will review your trading history at no cost and provide an initial assessment of your potential eligibility.

Q: What if I live outside the United States? A: U.S. securities class actions generally cover purchases on U.S. exchanges regardless of the investor's country of residence.

Q: Can I join a different law firm's lawsuit instead? A: Yes. Investors may choose which law firm to contact. Multiple firms often file competing complaints. The court may consolidate related cases and appoint a single lead counsel.

Q: How long will the lawsuit take to resolve? A: Securities class actions typically take two to four years from initial filing to resolution. Timing depends on the court schedule, case developments, and whether the matter is dismissed, settled, or litigated further.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (212) 363-7500

Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

Nu Holdings Ltd. (NYSE:NU) shares are sliding Monday along with other U.S.-listed Brazil stocks after Luiz Inácio Lula da Silva beat Flávio Bolsonaro in Sunday's presidential runoff.

Key Takeaways Viking Therapeutics reports Q3 results Oct. 28, with a consensus estimate of a $1-per-share loss.Phase III trials of oral and injectable VK2735 could deliver key data readouts in 2027.Viking holds $502 million in cash and raised $575 million in September, but faces dilution and competition. Viking Therapeutics (VKTX - Free Report) is set to report third-quarter 2026 earnings on Oct. 28, after market close. Because the company has no marketed drugs in its portfolio, it is not expected to record revenue. The Zacks Consensus Estimate pegs earnings at a loss of $1 per share.

Loss estimates for 2026 have slightly improved from $4.47 to $4.46 per share over the past 30 days. However, those for 2027 have remained unchanged at a loss of $4.08 over the same period.

Image Source: Zacks Investment Research

VKTX’s Earnings Surprise HistoryEarnings missed estimates in three of the trailing four quarters and beat the mark on one occasion, delivering a negative average surprise of 26.47%. In the last reported quarter, Viking’s earnings beat estimates by 9.09%.

Image Source: Zacks Investment Research

What Our Model Predicts for VKTXPer our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) have a good chance of delivering an earnings beat. This is not the case here. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.

Viking has an Earnings ESP of 0.00% and a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Factors Likely to Shape VKTX’s Upcoming ResultsInvestor attention is likely to have centered on Viking Therapeutics’ obesity pipeline, particularly its lead candidate, VK2735. A dual GLP1 and GIP receptor agonist, the drug is being developed as both subcutaneous (SC) and oral formulations. While Viking initiated two phase III studies of SC VK2735 last year, the company recently advanced the oral formulation into its own late-stage development program.

Investors may look for management commentary on the progress of the VANQUISH studies, which are evaluating once-weekly SC VK2735 over 78 weeks. VANQUISH-1 is assessing the drug in adults with obesity or overweight and at least one weight-related comorbidity, excluding those with type II diabetes (T2D), while VANQUISH-2 is evaluating the drug in adults with obesity or overweight who have T2D. With both studies fully enrolled, management may provide updates on the anticipated timing of data readouts, which are expected in 2027.

Management may also provide further details on the newly initiated phase III program for oral VK2735, including enrollment timelines and anticipated data readouts. The two SUNRISE studies broadly follow the framework of the VANQUISH studies but are smaller in scale and shorter in duration, with each evaluating treatment over 68 weeks.

Beyond developing oral and injectable formulations of VK2735, Viking is also exploring strategies to support long-term weight maintenance. After announcing encouraging results from the first part of a maintenance study last month that evaluated less frequent SC doses, the company recently started the second part of this study to evaluate oral VK2735 alongside less-frequent SC dosing regimens as potential options for maintaining weight loss. An update on this study is expected in 2027.

Investors may also look for updates on the ongoing phase I study on VK3019, Viking’s investigational dual amylin and calcitonin receptor agonist, which is being developed as a potential treatment for obesity.

Nevertheless, a single quarter’s results are not so important for long-term investors. Let us delve deeper to understand whether it would be a prudent move to buy, sell or hold the stock at present.

VKTX’s Stock Price Performance & ValuationYear to date, the stock has lost roughly 31% against the industry’s nearly 5% growth. It has also underperformed the broader Medical sector and the S&P 500 Index, as seen in the chart below.

VKTX Stock Underperforms Industry, Sector & S&P 500
Image Source: Zacks Investment Research

From a valuation standpoint, Viking is trading at a premium to the industry. Going by the price/book ratio, the stock currently trades at 7.53 times trailing 12-month book value, which is higher than 3.94 times for the industry.

Image Source: Zacks Investment Research

Our Investment Thesis on VKTX StockViking Therapeutics has several potential catalysts that could support its stock. With the phase III program for oral VK2735 now underway, investors will look for updates on study progress and development timelines. Viking expects to report results from the oral maintenance portion of the VK2735 study in 2027, which could provide further evidence of its potential for flexible, less-frequent dosing. We also expect data readouts from the VANQUISH studies next year. Positive findings could strengthen the drug’s commercial prospects and support Viking’s efforts to compete in the obesity-treatment market.

Viking’s financial position is another positive. The company held $502 million in cash, cash equivalents and short-term investments as of June 2026-end and raised approximately $575 million in gross proceeds through equity and convertible-note offerings in September. This should provide substantial funding for continued pipeline development and potential commercialization, although the financing also introduces shareholder dilution and debt obligations.

However, competition remains a key risk, with Eli Lilly (LLY - Free Report) and Novo Nordisk (NVO - Free Report) dominating the obesity-treatment market through established products and extensive commercial capabilities. Viking will need to demonstrate that VK2735 can compete effectively on efficacy, safety and dosing convenience. The company could also attract acquisition interest from larger pharmaceutical players seeking to strengthen their obesity portfolios, although any such possibility remains speculative.

How to Play VKTX Stock?We believe the recent decline could provide an opportunity for investors to buy or retain VKTX shares. Although clinical and competitive risks remain, favorable developments from VK2735 could help the stock regain momentum.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Hims between August 4, 2025 and July 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - October 26, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company shared consumers' health information with third-party advertising platforms; (2) the Company charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is "right for them;" (3) the foregoing conduct subjected the Company to regulatory scrutiny; (4) as a result of the foregoing, the Company was reasonably likely to incur fees and penalties; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On July 29, 2026, during market hours, the Federal Trade Commission announced it had filed a lawsuit against Hims "alleging that the telehealth provider shared consumers' sensitive health information about medical conditions with third-party advertising platforms despite claiming its services maintain consumers' privacy and deceives users about its billing and cancellation practices." On this news, Hims's stock price fell $4.32, or 14.73%, to close at $25.00 per share on July 29, 2026, on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Hims's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Hims class action, go to www.faruqilaw.com/HIMS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the Hims Securities Class Action Lawsuit:

What is the Hims securities fraud lawsuit about?

Faruqi & Faruqi, LLP has filed a securities class action lawsuit alleging that Hims & Hers Health, Inc. (NYSE: HIMS) made materially false and misleading statements to investors during the Class Period. The complaint alleges that the Company shared consumers' sensitive health information with third-party advertising platforms despite representing that its services maintain consumer privacy, and that the Company allegedly charged consumers for prescriptions almost immediately after intake form submission while telling consumers they would first be able to consult with a medical provider. The lawsuit further alleges that this conduct subjected Hims to regulatory scrutiny and made the Company reasonably likely to incur fees and penalties. On July 29, 2026, the Federal Trade Commission announced it had filed a lawsuit against Hims alleging these practices, and on that news Hims's stock price allegedly fell $4.32, or approximately 14.73%, to close at $25.00 per share on unusually heavy trading volume. As a result of the foregoing, the complaint alleges that Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Who may be eligible to participate in the lawsuit?

Investors who purchased or otherwise acquired securities of Hims & Hers Health, Inc. (NYSE: HIMS) on the NYSE exchange between August 4, 2025 and July 29, 2026, inclusive, may be eligible to participate in this class action lawsuit. Eligibility to participate in any potential recovery is not limited to investors who seek appointment as lead plaintiff; any investor who purchased Hims securities during the Class Period may be a class member. Eligible investors are encouraged to review their trading records to determine whether their purchases fall within the defined Class Period. Investors with questions about their eligibility may wish to consult with counsel to better understand their rights and options in connection with this litigation.

What is a lead plaintiff, and how can I seek appointment?

A lead plaintiff is a court-appointed representative who serves on behalf of all class members and plays an active role in directing the litigation, including working with counsel on case strategy and settlement decisions. Any investor who purchased Hims securities during the Class Period and suffered a loss may move the court for appointment as lead plaintiff, provided that motion is filed no later than November 2, 2026. Courts typically appoint the investor or group of investors with the largest financial interest in the litigation who also satisfy the requirements of Federal Rule of Civil Procedure 23 as lead plaintiff. Importantly, an investor need not seek appointment as lead plaintiff in order to participate in or share in any recovery that may result from the litigation. Investors who do not seek lead plaintiff status retain the right to remain members of the class and benefit from any judgment or settlement.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Hims securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320930

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Wall Street analysts expect Reddit Inc. (RDDT - Free Report) to post quarterly earnings of $1.30 per share in its upcoming report, which indicates a year-over-year increase of 62.5%. Revenues are expected to be $886.35 million, up 51.5% from the year-ago quarter.

Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.

Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.

While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.

Bearing this in mind, let's now explore the average estimates of specific Reddit Inc. metrics that are commonly monitored and projected by Wall Street analysts.

Analysts expect 'Revenue- Other revenue' to come in at $43.04 million. The estimate indicates a change of +21% from the prior-year quarter.

Analysts' assessment points toward 'Revenue- Advertising revenue' reaching $843.64 million. The estimate indicates a year-over-year change of +53.6%.

The consensus estimate for 'Revenue- United States' stands at $702.19 million. The estimate points to a change of +46.3% from the year-ago quarter.

The average prediction of analysts places 'Revenue- International' at $184.55 million. The estimate suggests a change of +75.8% year over year.

Analysts forecast 'DAUq (Daily Active Uniques) - U.S.' to reach 53.37 million. The estimate is in contrast to the year-ago figure of 51.60 million.

Based on the collective assessment of analysts, 'ARPU - U.S.' should arrive at $12.92 . Compared to the present estimate, the company reported $9.04 in the same quarter last year.

The consensus among analysts is that 'DAUq (Daily Active Uniques) - International' will reach 80.13 million. Compared to the current estimate, the company reported 64.40 million in the same quarter of the previous year.

The combined assessment of analysts suggests that 'ARPU - Global' will likely reach $6.67 . The estimate compares to the year-ago value of $5.04 .

It is projected by analysts that the 'DAUq (Daily Active Uniques) - Global' will reach 133.36 million. Compared to the present estimate, the company reported 116.00 million in the same quarter last year.

Analysts predict that the 'WAUq - Global' will reach 531.10 million. Compared to the current estimate, the company reported 443.80 million in the same quarter of the previous year.

According to the collective judgment of analysts, 'WAUq - International' should come in at 333.62 million. Compared to the current estimate, the company reported 256.00 million in the same quarter of the previous year.

The collective assessment of analysts points to an estimated 'WAUq - U.S.' of 197.49 million. The estimate is in contrast to the year-ago figure of 187.80 million.

View all Key Company Metrics for Reddit Inc. here>>>

Over the past month, Reddit Inc. shares have recorded returns of -3.7% versus the Zacks S&P 500 composite's -1.2% change. Based on its Zacks Rank #3 (Hold), RDDT will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Ichor Holdings (ICHR - Free Report) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

The earnings report, which is expected to be released on November 2, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus EstimateThis company is expected to post quarterly earnings of $0.45 per share in its upcoming report, which represents a year-over-year change of +542.9%.

Revenues are expected to be $330.19 million, up 38% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Ichor Holdings?For Ichor Holdings, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -0.55%.

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination makes it difficult to conclusively predict that Ichor Holdings will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Ichor Holdings would post earnings of $0.31 per share when it actually produced earnings of $0.34, delivering a surprise of +9.68%.

Over the last four quarters, the company has beaten consensus EPS estimates three times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Ichor Holdings doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Wall Street expects a year-over-year increase in earnings on higher revenues when Tempus AI (TEM - Free Report) reports results for the quarter ended September 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.

The earnings report, which is expected to be released on November 2, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis health care technology company is expected to post quarterly loss of $0.09 per share in its upcoming report, which represents a year-over-year change of +18.2%.

Revenues are expected to be $411.7 million, up 23.2% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 9.09% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Tempus?For Tempus, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +20.00%.

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination indicates that Tempus will most likely beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Tempus would post a loss of$0.13 per share when it actually produced a loss of -$0.04, delivering a surprise of +69.23%.

Over the last four quarters, the company has beaten consensus EPS estimates three times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Tempus appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

C3.ai, Inc. (AI - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Over the past month, shares of this company have returned +17%, compared to the Zacks S&P 500 composite's -1.2% change. During this period, the Zacks Computers - IT Services industry, which C3.ai falls in, has gained 11.9%. The key question now is: What could be the stock's future direction?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Earnings Estimate RevisionsHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

C3.ai is expected to post a loss of $0.22 per share for the current quarter, representing a year-over-year change of +12%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.3%.

For the current fiscal year, the consensus earnings estimate of -$0.76 points to a change of +43.7% from the prior year. Over the last 30 days, this estimate has changed +0.1%.

For the next fiscal year, the consensus earnings estimate of $0.46 indicates a change of +39.5% from what C3.ai is expected to report a year ago. Over the past month, the estimate has changed -2.1%.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for C3.ai.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

In the case of C3.ai, the consensus sales estimate of $53.09 million for the current quarter points to a year-over-year change of -29.4%. The $223.01 million and $248.78 million estimates for the current and next fiscal years indicate changes of -10.9% and +11.6%, respectively.

Last Reported Results and Surprise HistoryC3.ai reported revenues of $52.38 million in the last reported quarter, representing a year-over-year change of -25.4%. EPS of -$0.2 for the same period compares with -$0.37 a year ago.

Compared to the Zacks Consensus Estimate of $51.46 million, the reported revenues represent a surprise of +1.79%. The EPS surprise was +23.08%.

Over the last four quarters, C3.ai surpassed consensus EPS estimates three times. The company topped consensus revenue estimates three times over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

C3.ai is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about C3.ai. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

The market expects Atlas Energy Solutions Inc. (AESI - Free Report) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on November 2. On the other hand, if they miss, the stock may move lower.

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus EstimateThis company is expected to post quarterly loss of $0.26 per share in its upcoming report, which represents a year-over-year change of -100%.

Revenues are expected to be $255.72 million, down 1.5% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 2.86% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Atlas Energy Solutions Inc.?For Atlas Energy Solutions Inc., the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -2.86%.

On the other hand, the stock currently carries a Zacks Rank of #4.

So, this combination makes it difficult to conclusively predict that Atlas Energy Solutions Inc. will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Atlas Energy Solutions Inc. would post a loss of$0.12 per share when it actually produced a loss of -$0.18, delivering a surprise of -50.00%.

The company has not been able to beat consensus EPS estimates in any of the last four quarters.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Atlas Energy Solutions Inc. doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Expected Results of an Industry PlayerDT Midstream (DTM - Free Report) , another stock in the Zacks Oil and Gas - Integrated - United States industry, is expected to report earnings per share of $1.01 for the quarter ended September 2026. This estimate points to a year-over-year change of -10.6%. Revenues for the quarter are expected to be $333.93 million, up 6.4% from the year-ago quarter.

The consensus EPS estimate for DT Midstream has been revised 4.9% lower over the last 30 days to the current level. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -3.22%.

When combined with a Zacks Rank of #3 (Hold), this Earnings ESP makes it difficult to conclusively predict that DT Midstream will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates two times.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.